G1 Therapeutics Announces Updated Results from Phase 2 Trial of Trilaciclib in Combination with Chemotherapy Showed Statistically Significant Improvement in Overall Survival in Women with Metastatic Triple-Negative Breast Cancer
Qpex Biopharma to Provide First Public Presentations of Preclinical Data on the Novel Ultra-Broad-Spectrum Beta-lactamase Inhibitor QPX7728 for IV and Oral Products at 2019 ASM Microbe Meeting
Artizan Biosciences Announces Corporate Progress and Financing
Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases
Elligo Health Research Raises $20M to Connect More Physicians and Their Patients to Clinical Research as a Care Option
Qpex Biopharma Licenses Polymyxin Antimicrobial Program from Monash University to Address Drug-Resistant Infections
G1 Therapeutics Announces Positive Feedback from Trilaciclib End-of-Phase 2 Meeting with FDA; Expects to File NDA in 2020
HistoSonics, Non-Invasive Robotics Pioneer, Closes $54 Million Series C Financing Breakthrough medical platform offers vision of personalized tumor treatments with its novel sonic beam therapy
StrideBio and Takeda Sign Collaboration and License Agreement to Advance Novel Gene Therapies for Neurological Diseases
Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiology’s 68th Annual Scientific Session
Mycovia Pharmaceuticals Initiates Additional Phase 3 Clinical Study Evaluating VT-1161 for the Treatment of Vulvovaginal Candidiasis
Graybug Vision Appoints Frédéric Guerard as Chief Executive Officer Pharmaceutical Industry Veteran and Former Worldwide Business Franchise Head of Ophthalmology at Novartis
